NCT01081327已完成不适用
Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- Bleeding Complication
研究概览
简要总结
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.
研究设计
- 研究类型
- Observational
- 观察模型
- Ecologic Or Community
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prescription for Warfarin
- •Atrial Fibrillation
排除标准
- •Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
- •Conditions with increased risk of bleeding.
结局指标
主要结局
Bleeding Complication
时间窗: 10 years
Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.
Cardiovascular outcome
时间窗: 10 years
Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary CalciumAtherosclerosisNCT02376010Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center110
Unknown
不适用
GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life EvidenceAtrial FibrillationNCT02633982Japan Cardiovascular Research Foundation5,000
撤回
4 期
Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney DiseaseAtrial FibrillationChronic Kidney DiseaseNCT01668901Seoul National University Hospital
Unknown
不适用
Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and MetabolomicsBleedingAtrial FibrillationAnticoagulant TherapyNCT05181774Yue LI100
终止
3 期
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial FibrillationAtrial FibrillationNCT03839355Mayo Clinic34